Restoring miR-489 expression inhibits proliferation and tumor growth by targeting SHP2 and HER2, simultaneously suppressing ERK signaling [251], whereas miR-16 upregulation induced by trastuzumab impairs the growth of trastuzumab and lapatinib-resistant cells [252]. This evidence concerns the gene ERBB2 and neoplasm.